Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | INPP5B | P32019 | 1/20 | 0.34 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727743 | 0.76 | INPPL1 (0.57) | INPPL1INPP5BINPP5ASRCKDM4E | |
| SCHEMBL28972481 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1GAATSHR | |
| SCHEMBL27715051 | 0.75 | SRC (0.55) | SRCKDM4EALDH1A1POLB | |
| SCHEMBL5716668 | 0.68 | CA1 (0.36) | ALDH1A1NPC1TSHR | |
| SCHEMBL820783 | 0.66 | CA2 (0.35) | — | |
| SCHEMBL497602 | 0.65 | KDM4E (0.47) | INPPL1INPP5BINPP5ASRCKDM4E | |
| SCHEMBL28621325 | 0.65 | CA1 (0.56) | SRCKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29704034 | 0.64 | TSHR (0.70) | SRCKDM4EALDH1A1PTK2BTSHR | |
| Fluoride SCHEMBL31047191 | 0.63 | KDM4E (0.46) | INPPL1INPP5BINPP5ASRCKDM4E | |
| SCHEMBL16029706 | 0.63 | CA2 (0.48) | SRCUSP2ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335726-B1 | MODIFIED PRODRUG FORMS OF AP | NANOTHERAPEUTICS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1335726-A4 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-6911460-B2 | Antiviral agents and methods of treating viral infections | VION PHARMACEUTICALS, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1335726-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | Vion Pharmaceuticals, Inc. (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | disclosed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6458816-B1 | ANTICANCER AGENTS | VION PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030424-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | INPPL1 1177/4885INPP5B 1139/4885INPP5A 1228/4885 |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | INPPL1 28/4885INPP5B 91/4885INPP5A 249/4885 |
| US-20050261251-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | INPPL1 1177/4885INPP5B 1139/4885INPP5A 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.